AUTL

Autolus Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 3/10
  • Value↓ 0/10
Autolus Therapeutics sales and earnings growth
AUTL Growth
Neutral
  • Revenue Y/Y↑ 927.84%
  • EPS Y/Y↓ -23.86%
  • FCF Y/Y↓ -5.79%
Autolus Therapeutics gross and profit margin trends
AUTL Profitability
Neutral
  • Gross margin ↓ -11.20%
  • EPS margin↓ -312.00%
  • ROIC 5Y↓ -43.64%
Autolus Therapeutics net debt vs free cash flow
AUTL Risk
Poor
  • Debt / Equity↑ 3.4
  • Debt / FCF↓ 0.8
  • Interest coverage↓ -6.7

Autolus Therapeutics stock volatility is in-line with the overall market. We give it a Poor risk rating.

↗ More Biotechnology stocks